Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Moodys
Julphar
US Army
Colorcon
Harvard Business School

Generated: April 24, 2019

DrugPatentWatch Database Preview

DEFINITY Drug Profile

« Back to Dashboard

When do Definity patents expire, and when can generic versions of Definity launch?

Definity is a drug marketed by Lantheus Medcl and is included in one NDA. There are four patents protecting this drug.

This drug has forty-two patent family members in thirty countries.

The generic ingredient in DEFINITY is perflutren. One supplier is listed for this compound. Additional details are available on the perflutren profile page.

Summary for DEFINITY
International Patents:42
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 32
Clinical Trials: 43
Patent Applications: 1,497
Formulation / Manufacturing:see details
Drug Prices: Drug price information for DEFINITY
Prior Art and Litigation SupportOrder Prior Art and Litigation support for DEFINITY
DailyMed Link:DEFINITY at DailyMed
Drug patent expirations by year for DEFINITY
Generic Entry Opportunity Date for DEFINITY
Generic Entry Date for DEFINITY*:
➤ Sign Up
Constraining patent/regulatory exclusivity:
➤ Sign Up
NDA:
021064
Dosage:
INJECTABLE;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for DEFINITY
Drug ClassContrast Agent for Ultrasound Imaging
Mechanism of ActionUltrasound Contrast Activity
Synonyms for DEFINITY
1,1,1,2,2,3,3,3-Octafluoropropane
1,1,1,2,2,3,3,3-octakis(fluoranyl)propane
218599-63-4
300408-51-9
76-19-7
A838638
AC1L1MIR
AC1Q4IBX
AKOS006228213
AN-23892
AN-37829
C-50894
C3F8
C3F8-gas
CHEBI:31980
CHEMBL1663
CK0N3WH0SR
CTK5E2580
D01738
DB-056033
DB00556
Definity (TN)
DMP 115
DMP-115
DTXSID9052503
EC 200-941-9
EINECS 200-941-9
FC 218
FC 218 (refrigerant)
FCH918400
Flutec PP30
Freon 218
FS-069
FS069
FT-0621948
FT-0631321
Genetron 218
HFC 218
HSDB 8074
I14-14876
KB-59511
liposome-encapsulated perfluoropane microsphere
LS-120891
MRX 115
MRX-115
OCTAFLUOROPROPANE
octafluoropropane-lipid microsphere
Octafluoropropaneor Refrigerant gas R 218
Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]
Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]
Octafluorpropan
Oktafluorpropan
Optison
Optison (Salt/Mix)
Perfluoropropane
Perfluoropropane (PFC-218) 99.9%
Perfluoropropane 99+%
Perfluoropropaneminimum
Perflutren
Perflutren (JAN/USAN/INN)
Perflutren [USAN:INN:BAN]
Perflutren [USAN]
Perflutren and Human Albumin
Perflutren Lipid Microsphere
Perflutren lipid microspheres
Perflutren Protein-Type A Microspheres injection
Perflutren-lipid microsphere
PFC 218
Propane, 1,1,1,2,2,3,3,3-octafluoro-
Propane, octafluoro-
Propane,1,1,1,2,2,3,3,3-octafluoro-
QYSGYZVSCZSLHT-UHFFFAOYSA-N
R 218
RC 218, PFC 218
SBB090673
UN 2424
UN2424
UNII-CK0N3WH0SR
YM454
ZINC8214651
ZX-AP010865

US Patents and Regulatory Information for DEFINITY

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for DEFINITY

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for DEFINITY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0712293 SPC/GB07/031 United Kingdom ➤ Sign Up PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
0712293 C300267 Netherlands ➤ Sign Up PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
0712293 0790017-8 Sweden ➤ Sign Up PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Citi
Baxter
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2019 - 2020
 NCE-1 Generic Application Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.
Links

Follow DrugPatentWatch: